首页> 外文期刊>International Journal of Pediatrics and Adolescent Medicine >Intravenous and intramuscular therapy in near fatal asthma. A response to Al-Shamrani
【24h】

Intravenous and intramuscular therapy in near fatal asthma. A response to Al-Shamrani

机译:静脉内和肌肉内疗法在致命哮喘附近。对Al-Shamrani的回应

获取原文
       

摘要

The invited review by Al-Shamrani et?al. (2020) [] failed to address the management of a patient having an asthma attack who arrives in the Emergency Department with respiratory failure or in a moribund condition. The only route available for drug therapy in these patients is intravenously (IV) or intramuscularly in a final attempt to reduce bronchoconstriction. This could avoid tracheal intubation and lung ventilation, or make these procedures safer (Sellers, 2013; Williams et?al., 1992) [,] for the patient if some bronchodilation occurs. Intubation and ventilation prevent coughing but tenacious mucus remains which blocks the bronchi. There are no randomised controlled trials or national asthma guidelines to inform practice at this stage of the disease, especially in under 18 year olds, so case report evidence, experience, common sense, and pharmacological principles must be engaged to save the patient’s life.
机译:由Al-Shamrani et?al的邀请审查。 (2020)[]未能解决具有哮喘袭击的患者的管理,患有呼吸失败或垂死的病症。在这些患者中唯一可用于药物治疗的途径静脉内(IV)或肌肉内肌肉注射,以减少支气管细胞。这可以避免气管插管和肺气通风,或使这些程序更安全(卖家,2013;威廉姆斯et?al。,1992)[,]如果发生一些支气管扩张。插管和通风可以防止咳嗽但顽强的粘液仍然阻挡了支气管。没有随机对照试验或国家哮喘指南在疾病的这种阶段为实践提供信息,特别是在18岁以下,因此报告证据,经验,常识和药理学原则必须参与拯救患者的生命。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号